Citations

Clear

2960 citation(s) found for "Kim, P".

Exploring GPCR-mediated optogenetic modulation of seizure network in a pig model of Temporal Lobe Epilepsy
Chang, Su-Youne , Bar-Or, Karni Lev, Mívalt, Filip , Maltais, Daniela D., Kfir, Yoav , Kim, Inyong , Hershko, Matan, Daily, Jenn, Swissa, Evyatar , Devore, Sasha, Eldar, Yotam, Worrell, Gregory A., Mivalt, Filip , Kim, Jiwon W. , Levi, Ofir , Devore, Sasha, Yizhar, Ofer , Eldar, Yotam, Worrell, Gregory A.

Mayo Clinic

No container title available | January 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.23.634545 Get It

Abstract Rationale Optogenetics offers unmatched cellular specificity and control over cellular activity. Various opsins have been tested in animal models of epilepsy, each contributing to our understanding of seizure circuit dynamics. However, inhibitory optogenetic tools based on microbial rhodopsins have low light sensitivity and, thus, are less suitable for applications involving larger brains. We evaluated eOPN3, a red-shifted, highly sensitive inhibitory G-protein coupled receptor opsin in a porcine seizure model using integrated electro-optical sensing and modulation. The results demonstrated the feasibility of eOPN3 circuit modulation in a large animal epilepsy model. Methods MRI-guided stereotactic surgery was used to deliver 20–60 µL of AAV-eOPN3 (AAV5-/AAV9-CaMKII-eOPN3-mScarlet) into the hippocampus (HPC) of three Göttingen minipigs. Each hemisphere received either an active or a control viral vector (AAV5/9-CaMKII-mScarlet) with gadolinium to visualize the injection sites and diffusion volume via post-operative MRI. Two to three months post-injection, bilateral deep brain stimulation electrodes integrated with optic fibers were stereotactically implanted into the anterior nucleus of the thalamus (ANT) and HPC to assess: 1) opsin expression using fiber photometry, 2) optogenetic modulation of stimulation evoked response potentials (SERPs), 3) induction and propagation of seizure-like activity via intrahippocampal kainic acid (KA) injection, and 4) optogenetic modulation of KA-induced seizure activity. After the electrophysiology recording, brains were harvested for histological analysis to evaluate injection target precision, eOPN3 expression, and estimate eOPN3-modulated volume. Results eOPN3 expression was confirmed during surgery via fiber photometry. ANT electrical stimulation elicited robust SERPs in the HPCs, which were attenuated by HPC light illumination. HPC stimulation similarly induced SERPs in the ipsilateral ANT and the contralateral HPC. The HPC stimulation-induced SERPs were significantly reduced by illuminating the site of the recording areas, the ipsilateral ANT and the contralateral HPC, demonstrating the optogenetic inhibition of the synaptic release from the HPC. KA injection into the HPC induced 20-30 Hz seizure-like activity. The ANT and HPC light illumination suppressed the localized KA-induced seizure activity in the early stage. However, after the generalization of KA-induced seizures, the ANT-HPC illumination lost efficacy for the control of seizures. Histological analysis confirmed eOPN3 expression in the HPC, ANT and other Papez circuit nodes. Conclusion Our pilot study highlights that eOPN3-mediated inhibition alters SERP and the latency and spread of KA-induced seizure-like activity. We developed a platform incorporating pre- and postoperative MRI for precise viral vector delivery, real-time fiber photometry for quantifying opsin expression, and integrated electro-optical sensing and stimulation to assess optogenetic efficacy in a large animal model. The large animal model provides a solid foundation for future translational research to develop electro-optical devices and cellular therapies for human epilepsy.
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
Skoulidis, Ferdinandos , Govindan, Ramaswamy , Vincent, Mark , Wekken, Anthonie J. van der , Aransay, N. Reguart, O’Byrne, Kenneth J. , Girard, Nicolas , Griesinger, Frank , Nishio, Makoto , Häfliger, Simon, Lindsay, Colin R. , Paulus, Astrid, Papakotoulas, Pavlos, Kim, Sang‐We , Gennatas, Spyridon , Mehta, Bhakti, Kormany, William, Sylvester, Brooke E., Ardito-Abraham, Christine , Langen, Adrianus J. de , Girard, Nicolas , Pasello, Giulia , de Langen, Adrianus Johannes , van der Wekken, Anthonie J , Govindan, Ramaswamy , Li, Bob T. , Hochmair, Maximilian Johannes , Haefliger, Simon , Reinmuth, Niels , Ferreira, Carlos Gil , Duruisseaux, M. , Dimou, Anastasios , Nduka, Chidozie U , Wang, Yang

Mayo Clinic

The Oncologist | January 23, 2025 | Volume: 30 | Issue: 1 | Pages: No page available

10.1093/oncolo/oyae356 | PMID 39846981 Get It

Abstract Introduction We describe the safety of sotorasib monotherapy in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) and discuss practical recommendations for managing key risks. Methods Incidence rates of treatment-related adverse events (TRAEs) were pooled from 4 clinical trials: CodeBreaK 100 (NCT03600883), CodeBreaK 101 (NCT04185883), CodeBreaK 105 (NCT04380753), and CodeBreaK 200 (NCT04303780) and graded according to CTCAE v5.0. Adverse events were deemed sotorasib-related per investigator causality assessment. Results In the pooled population (n = 549), TRAEs were reported in 388 (70.7%) patients (grade 1: 124 [22.6%]; grade 2: 117 [21.3%]; grade ≥ 3: 147 [26.8%]). Gastrointestinal and hepatic TRAEs, including diarrhea (171 [31.1%]), nausea (80 [14.6%]), elevated alanine aminotransferase (ALT; 68 [12.4%]), and elevated aspartate aminotransferase (AST; 67 [12.2%]) were the most common (≥10%). Dose interruption and dose reduction of sotorasib resulted in the resolution of >90% of diarrhea events; median time to resolution were 18.0 days and 22.0 days, respectively. Similar trends were observed for elevated ALT and AST events. Patients who stopped immunotherapy <3 months before initiating sotorasib had a higher incidence of treatment-related hepatotoxicity (80/240 [33.3%]) than those who stopped immunotherapy ≥3 months before initiating sotorasib (26/188 [13.8%]). Treatment-related pneumonitis/interstitial lung disease (ILD) and corrected QT (QTc) prolongation were observed in 9 (1.6%) and 4 (0.7%) patients, respectively. Two (0.4%) patients died with TRAEs, 1 with ILD whose ultimate cause of death was disease progression, and the other with an unknown cause. Conclusions Sotorasib has a well-characterized safety profile in patients with KRAS G12C-mutated advanced NSCLC, and key risks are manageable with dose modification.
Kainic Acid Pig Model of Hippocampal Epilepsy
Mívalt, Filip , Maltais, Daniela D., Kim, Inyong , Began, Patrik, Lopez, Andrea Duque , Krakorova, Veronika, Winter, Bailey , Kuo, Cheng Yen, Sharma, Shelja, Harty, Elizabeth S., Kim, Luke H., Gregg, Nicholas, Montonye, Dan , Gow, Christopher, Miller, Kai J. , Leyde, Kent, Chang, Su-Youne , Gregg, Nicholas M. , Kremen, Vaclav , Gregg, Nicholas M , Duque Lopez, Andrea M , Mivalt, Filip , Kim, Jiwon W. , Kuo, Cheng Yen, Sharma, Shelja, Harty, Elizabeth S., Kim, Luke H., Montonye, Dan , Gompel, Jamie J. Van , Křemen, Václav , Worrell, Gregory A.

Mayo Clinic

No container title available | January 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.22.634312 | PMID 39896655 Get It

Abstract Translational large-animal models that can accommodate human-scale implantable devices are essential for advancing neuromodulation therapies in epilepsy. This study establishes a kainic acid (KA)-induced porcine model of mesial temporal lobe epilepsy (mTLE) using clinical imaging, stereotactic surgery, and a fully implantable neural stimulation and recording (INSR) device designed for humans. Seven pigs (six KA-treated and one saline control) underwent MRI-guided stereotactic implantation of electrodes targeting bilateral hippocampus (HPC) and anterior thalamus (ANT), followed by intra-hippocampal KA or saline infusion. Local field potentials (LFP) were recorded continuously with synchronized video monitoring. Seizures and LFP interictal epileptiform-like discharges (IEDs) were quantified using validated automated detectors. Histology was performed in the saline control and the longest surviving KA-treated pig. Intra-hippocampal KA infusion induced acute status epilepticus in all (6/6) treated pigs. Four animals survived to chronic monitoring with spontaneous seizures observed in three pigs (2,733 seizures; mean duration of 27.2 ± 17.6 seconds). IEDs were observed in bilateral HPC of all animals, including saline control, with higher rates in the lesioned HPC (p <0.0001). While the IED morphology is consistent with epileptiform activity; IEDs alone are not specific for epilepsy and physiological transients (e.g. sharp-wave ripples) and injury-related hyperexcitability or strain-specific hyperexcitability cannot be excluded. Histological analysis revealed patchy neuronal loss and cytoarchitectural changes in HPC. This porcine model reproduces electrophysiological features of human mTLE. This approach provides a powerful translational bridge for developing and testing next-generation INSR and neuromodulation strategies in freely behaving large animals.
Qualitative Study of Health Care Professional Perspectives on Recruiting Minority Patients in Cancer Trials
Price, Katharine A. , Warsame, Rahma , Toure, Elhadji A., O’Shea, Molly , Ellingson, Sara A., Asiedu, Gladys B. , Asiedu, Gladys B , Price, Katharine A R , Toure, Elhadji A., Kim, Yong-Hun , Cook, Joselle

Mayo Clinic

Health Equity | January 21, 2025 | Volume: 9 | Issue: 1 | Pages: No page available

10.1089/heq.2024.0184 | PMID 40123842 Get It

Background: Underrepresented minority (URM) patients enroll in cancer clinical trials at low rates. We studied the perspectives of health care professionals to better understand the challenges and potential facilitators of recruiting URM patients into clinical trials. Methods: A purposeful sampling approach was utilized to recruit health care professionals and clinical research staff who recruited and cared for URM patients in a therapeutic cancer clinical trial at any Mayo Clinic site, from July 2018 through October 2021.Data were gathered using a semistructured qualitative interviews. Participants were interviewed about the challenges of recruiting URM patients into cancer clinical trials and possible strategies for improving URM patient enrollment. Data were analyzed using a thematic analysis. Results: Of the key themes that emerged from participant interviews ( n = 28), perceived barriers to recruiting URM patients into clinical trials included lack of workforce diversity, underutilization of patient navigators, ineffective community outreach and patient recruitment, restricted access to diverse patient populations, and restrictive clinical trial eligibility criteria. Other barriers reported were lack of insurance and access to care and transportation, low socioeconomic status, and mistrust of health care and research. Strategies suggested for improving the recruitment of URM patients into clinical trials included: diversifying and adding research staff, increasing and improving community outreach and advocacy, partnering with clinics closer to patients, increasing monetary and logistical support for patient participation, creating opportunities that build and enhance trust, and systematically examining and modifying clinical trial eligibility criteria. Conclusions: Our findings reveal barriers that have limited URM patient inclusion in cancer clinical trials and highlight strategies to overcoming these barriers.
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Andrews, Jack R. , Kim, Yohan , Horjeti, Edlira , Arafa, Ali , Bruycker, Aurélie De , Phillips, Ryan , Song, Daniel Y. , Sartor, Oliver , Orme, Jacob J. , Chaudhuri, Aadel A. , Kiess, Ana P. , Sutera, Philip , Mercier, Carole , Arafa, Ali T. , Gunn, Heather , De Bruycker, Aurélie , Phillips, Ryan , Song, Daniel , Childs, Daniel S , Sartor, A Oliver , Orme, Jacob J , Chaudhuri, Aadel A , Tran, Phuoc T , Kiess, Ana , Sutera, Philip , Mercier, Carole , Ost, Piet , Park, Sean S , Lucien, Fabrice , Gunn, Heather , Childs, Daniel S. , Park, Sean S. , Lucien, Fabrice

Mayo Clinic

Clinical Cancer Research | January 16, 2025 | Volume: 31 | Issue: 6 | Pages: 1142-1149

10.1158/1078-0432.ccr-24-3027 | PMID 39820657 Get It

Abstract Purpose: Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong androgen-deprivation therapy–free survival or progression-free survival (PFS) in patients with metachronous oligometastatic castration-sensitive prostate cancer (omCSPC). Although most patients with omCSPC have a more modest delay in progression, a small subset achieves a durable response following SABR. We investigated the prognostic and predictive value of circulating prostate-specific membrane antigen-positive (PSMA+) extracellular vesicles (EV) and PSA in a biomarker correlative study using blood samples from three independent patient cohorts. Experimental Design: Plasma samples from 46 patients with omCSPC on the ORIOLE trial and 127 patients with omCSPC on the STOMP trial protocol treated with SABR were included in the study. Pre-SABR PSMA+EV levels (EV/mL) were measured by nanoscale flow cytometry. Kaplan–Meier curves and logistic regression models were used to determine the association of PSMA+EV and PSA levels with clinical outcomes. Results: In the pooled cohorts, the median biochemical PFS were 26.1 and 15.0 months (P = 0.005), and the median radiographic PFS were 36.0 and 25.0 months (P = 0.003) for PSMA+EV-low and -high groups, respectively. The combination of pre-SABR low levels of both PSMA+EV and PSA was associated with a lower risk of radiographic progression (HR, 0.34, 95% confidence interval, 0.18–0.58; P = 0.0002). In the ORIOLE cohort, which included both an SABR arm and an observation arm, low PSMA+EV was predictive of benefit from SABR (P = 0.012). Conclusions: PSMA+EV is a novel prognostic and predictive biomarker of radiographically occult tumor burden in omCSPC. PSMA+EV may inform clinical decisions about identifying patients who will achieve a durable benefit from consolidative SABR alone.
Blood Culture Use in Medical and Surgical Intensive Care Units and Wards
Hsu, Yea‐Jen , Salinas, Alejandra , Gadala, Avinash , Bower, Chris , Degnan, Kathleen, Dhaubhadel, Pragya, Drees, Marci , Feeser, Baevin , Fisher, Mark , Flynn, Cynthia E. , Gettler, Erin , Glaser, Laurel , Johnson, J. Kristie, Kim, Justin , Martinez, Marvin, Mermel, Leonard A. , Pepe, Dana , Robinson, Evan D. , Rodriguez‐Nava, Guillermo , Salinas, Jorge , Schrank, Gregory M. , Shah, Aditya , Spivak, Emily S , Stewart, Kathleen O., Wasylyshyn, Anastasia , Cosgrove, Sara E. , Fabre, Valeria , Carroll, Karen C. , Boyd, Sarah, Diekema, Daniel J. , Ford, Bradley , Howard‐Anderson, Jessica , Mathers, Amy J. , Moehring, Rebekah W. , Nelson, George E. , O’Horo, John C. , Ryder, Jonathan H. , Shelly, Mark , Talbot, Thomas R. , Schooneveld, Trevor Van

Mayo Clinic

JAMA Network Open | January 15, 2025 | Volume: 8 | Issue: 1 | Pages: e2454738

10.1001/jamanetworkopen.2024.54738 | PMID 39813030 Get It

ImportanceBlood culture (BC) use benchmarks in US hospitals have not been defined.ObjectiveTo characterize BC use in adult intensive care units (ICUs) and wards in US hospitals.Design, Setting, and ParticipantsA retrospective cross-sectional study of BC use in adult medical ICUs, medical-surgical ICUs, medical wards, and medical-surgical wards from acute care hospitals from the 4 US geographic regions was conducted. Critical access hospitals, less than 6 months of BC data, and non-US hospitals were excluded. The study included BC use data from September 1, 2019, to August 31, 2021. Data were analyzed from February 23 to July 14, 2024.Main Outcomes and MeasuresThe primary outcome was BC use per 1000 patient-days. Adjusted means with 95% CIs were calculated using mixed-effects negative binomial regression models adjusted for unit type, hospital bed size, geographic region, seasonality, and state COVID-19 case load, with random intercepts accounting for clustering at unit and hospital levels. Secondary outcomes included blood culture positivity, single BCs, BC contamination, and minimum threshold for BC use where blood culture positivity would be optimized.ResultsA total of 362 327 blood cultures were analyzed from 27 medical ICUs, 35 medical-surgical ICUs, 121 medical wards, and 109 medical-surgical wards from 48 hospitals in 19 states and the District of Columbia. The adjusted mean BC use per 1000 patient-days was 273.1 (95% CI, 270.2-275.9) for medical ICUs, 146.0 (95% CI, 144.5-147.5) for medical-surgical ICUs, 80.3 (95% CI, 79.8-80.7) for medical wards, and 65.1 for medical-surgical wards. Blood culture use was significantly higher across all 4 unit types in hospitals with more than 500 beds compared with 500 or less beds and in the West-Midwest compared with other regions. Single blood culture and positive blood culture rates were below 10% across all 4 unit types. Of the 292 units, 97% had a mean BC contamination rate within 3% of the recommended threshold, and 51% were within 1%. The minimum BC use thresholds (ie, BC use below this number may represent undertesting) were 120 BCs per 1000 patient-days for medical ICUs, 80 BCs per 1000 patient-days for medical-surgical ICUs, and 30 BCs per 1000 patient-days for medical-surgical wards.Conclusions and RelevanceThe findings of this study suggest that blood culture positivity may help determine appropriate BC use for individual unit types.
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2025
Wood, Douglas E. , Kazerooni, Ella A. , Argento, Christine, Baines, Jonathan, Boer, Brian, Donington, Jessica , Eapen, Georgie A. , Ferguson, J. Scott , Hou, Lifang , Klippenstein, Donald, Kolansky, Ana S., Leung, Ann N. , Mazzone, Peter J. , Merritt, Robert E. , Norris, Kim, Onaitis, Mark W. , Pipavath, Sudhakar, Puri, Varun , Raz, Dan J. , Reddy, Chakravarthy, Reid, Mary E. , Sandler, Kim L. , Sears, Catherine R. , Tanoue, Lynn, Thacker, Amber L., Tong, Betty C. , Wei, Benjamin , McCullough, Beth, Ramakrishnan, Swathi , Hou, Lifang , Leung, Ann , Aberle, Denise R. , Brown, Lisa Marie , Kumar, Rohit , Leard, Lorriana E. , Sands, Jacob , Schabath, Matthew B. , Studts, Jamie L. , Thacker, Amber L., Travis, William D. , Westover, Kenneth D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 15, 2025 | Volume: 23 | Issue: 1 | Pages: No page available

10.6004/jnccn.2025.0002 | PMID 39819601 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening provide criteria for selecting individuals for screening and offer recommendations for evaluating and managing lung nodules detected during initial and subsequent annual screening. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Wixner, Jonas , Polydefkis, Michael , Ueda, Mitsuharu , Bender, Shaun, Jay, Patrick Y. , Yureneva, Elena, group, patisiran Global OLE study, Vita, Giuseppe, Rizzo, Vincenzo , Wiesman, Janice F. , Lau, Vincent , DeLong, Douglas, May, John J., Delmont, Émilien , Pouget, Jean, Grapperon, Aude‐Marie , Campana-Salort, Emmanuelle, Coutinho, Conceição de Azevedo, Campos, Catarina Falcão de , Coelho, Teresa , Reis, Antonio Hipólito, Pérez, Javier Martínez , Silva, Ana Martins da, Alves, Cristina , Cardoso, Márcio , Valdrez, Kátia, Monte, Julia R, Novais, Marta , Guimarães, Nádia, Cardoso, Inês , Freitas, Mónica, Ferreira, Natália , Kuzume, Daisuke , Morimoto, Yuko, Gauvain, Clément , Migaud-Chervy, Maria-Claire, Deplanque, Dominique , Jozefowicz, Elsa, Théaudin-Saliou, Marie, Cauquil-Michon, Cécile, Labeyrie, Céline , Not, Adeline , Lecoq, Anne-Lise , Stephant, Maeva, Echaniz‐Laguna, Andoni , Becquemont, Laurent , Beaudonnet, Guillemette , Eliahou, Ludivine , Slama, Michel , Signaté, Aïssatou , Darche, Paola, Grimaud, Jérôme, Berthelot, Emeline, Inamo, Jocelyn , Gendre, Thierry , Arrouasse, Raphaele , Ernande, Laura , Salhi, Hayet, Choumert, Ariane , Charlin, Cyril, Megelin, Thomas, Brannagan, Thomas H., Tsang, Steven, Wajnsztajn, Fernanda, Shije, Jeffrey, Ulane, Christina, Kleyman, Inna , Weimer, Louis H., Cioroiu, Comana , Kleopa, Kleopas A. , Zamba‐Papanicolaou, Eleni , Tada, Satoshi , Nagai, Masahiro , Ando, Rina, Yamanishi, Yuki , Overcash, J. Scott , Green, Sinikka, Coskun, Derya J, Manos, Paul S. , Zepeda, Karla A, O’Riordan, William, Cortese, Andrea , Bernardo, Daniela, Paolantonio, Andrea Di , Guglielmino, Valeria , Kristen, Arnt V. , Nagel, Christian , Siepen, Fabian aus dem , Hein, Selina , Campistol, Josep M. , Marín, Lida María Rodas, Pelicano, Josep Miquel Blasco, Dávila, Lucía Galán, Cordoba, Vanesa Pytel, Sola, A. Guerrero, Feijoo, Julián García, Isla, Leopoldo Pérez de , Moreira, Carolina Lavigne , Marques, Vanessa Daccach , Beamud, Francisco Muñoz, Borrachero, Cristina, Sanz, Mónica, Oliver, E, Moreno, Juan González, Martinez, J. Michael, Descals, Cristina, Usón, Mercedes, Vega, Francisco Jose, Figuerola, Antoni, Montalà, Carles, Abreu, Aline França de , Silva, Moises Dias da, Rosa, Renata Gervais de Santa, Berensztejn, Amanda Cardoso, Guedes, Mariana de Andrade, Lautre, Andrea, Orellana, Lucas, Briseño, Maria Alejandra González-Duarte, Parra, David Rivera de la, Reyes, Jose Pablo Hernandez, Alba, Maria del Mar Saniger, Parman, Yeşim , Serbest, Nail Güven , Durmuş, Hacer , Karamürsel, Saçit , Elitok, Ali, Inan, Nermin G Sirin, Altinkurt, Emre, Polydefkis, Michael, Allen, Adriane C, Chaudhry, Vinay , Jarrett, R. J., Bressler, Neil M. , Khoshnoodi, Mohammad , Lui, Alvin T, Chung, Tae , Vista, Geno, Shah, Syed Mahmood , Hamaguchi, Hirotoshi , Oda, Tetsuya , Shimomura, Masahiro, Kim, Hee Jin, Misumi, Yohei , Nomura, Toshiya , Tateishi, Takahisa , Mauricio, Elizabeth A. , Dimberg, Elliot L., Fonder, Amie , Hobbs, Miriam, Dyck, P. James B. , Leung, Nelson , Hwa, Yi L. , Kapoor, Prashant , Kumar, Shaji , Dingli, David , Gove, Linde E., Dalia, Samir , Croy, David, Holding, Tim, Gorevic, Peter D., Su, Jen-Jen , Lin, Chao-Wen, Ajroud‐Driss, Senda , Sufit, Robert , Li, John-Michael, Freimer, Miriam , LoRusso, Samantha, Aso, Yasuhiro , Kim, Byoung‐Joon , Kim, JuHyeon, Jeon, Eun‐Seok , Seok, Jin Myoung , Park, Jae Hong , Sekijima, Yoshiki , Kato, Naga-aki, Hineno, Akiyo , Kodaira, Minori , Yoshinaga, Tsuneaki , Takasone, Ken, Miyahara, Teruyoshi, Takahashi, Yusuke , Matsumoto, Kazuhiko , Lin, Kon-Ping, Lee, Yi‐Chung , Wixner, Jonas, Pilebro, Björn, Nordh, Erik, Chermenina, Maria, Nygren, Anneli, Tournev, Ivaylo, Zhelyazkova, Sashka , Cherneva, Zheyna , Sarafov, S., Cherninkova-Gopina, Sylvia, Vorona, Elena, Huesing-Kabar, Anna, Schilling, Matthias , Kabar, Iyad , Martinez–Naharro, Ana , Chacko, Liza , Cohen, Oliver , Law, Steven , Rezk, Tamer , Quan, Dianna , Dixon, Stacy, Fridman, Vera , Low, Soon-Chai , Mezei, Michelle M. , Jack, Kristin, Wade, N. Kevin, Lopate, Glenn, Geisler, Stephanie , Sommerville, R. Brian, Florence, Julaine, Stewart, Graeme J., Taylor, Mark , Suan, Daniel, Dingli, David , Gillmore, Julian D , Lee, Yi-Chung , Karamursel, Sacit , Adams, David , Berk, John L. , Conceição, Isabel , Dispenzieri, Angela , Peltier, Amanda , Bender, Shaun , Capocelli, Kelley, Obici, Laura , group, patisiran Global OLE study, Vita, Giuseppe, Russo, Massimo , Mazzeo, Anna Teresa , Gentile, Luca, Kaku, Michelle C. , Lau, Vincent, Dalton, James, May, John, Attarian, Shahram , Verschueren, Annie , Campana-Salort, Emmanuelle, Neves, Carlos, Santos, Miguel Oliveira , Coelho, Teresa, Correia, Nuno, Perez, Javier M, Silva, Ana Martins da, Ramalho, Joana, Yamasaki, Masahiro , Morimoto, Yuko, Tard, Céline , Hachulla, É. , Lebellec, Loïc , Théaudin, Marie , Al‐Salameh, Abdallah , Algalarrondo, Vincent , Rousseau, Antoine , Planté‐Bordeneuve, Violaine , Ayache, Samar S. , Corvoisier, Philippe Le , Waters, Michael, Manos, Paul, Lozza, Alessandro , Merlini, Giampaolo , Rosti, Vittorio , Sabatelli, Mario , Bisogni, Giulia , Luigetti, Marco , Romano, Ângela , Nienhuis, Hans L. A. , Neshige, Shuichiro , Horga, Alejandro , Feijoo, Julián García, Marques, Wilson , López, Inés AL, Sanz, Monica, Martinez, Jose M Gamez, Waddington‐Cruz, Márcia , Abreu, Aline Souza de, Silva, Moises Dias da, Pinto, Marcus Vinícius , Pinto, Luiz Felipe , Barroso, Fábio , Briseno, Maria Alejandra Gonzalez Duarte, Cárdenas‐Soto, Karla , Cantú-Brito, Carlos Gerardo , Şahin, Erdi , Çakar, Arman , İNAN, NERMİN GÖRKEM ŞİRİN, Polydefkis, Michael, Jarrett, Raquel, Singh, Mandeep , Judge, Daniel P. , Lui, Alvin T, Vista, Geno, Shimomura, Masahiro, Scheid, Christof , Holtick, Udo , Oh, Jeeyoung , Kim, Hee Jin, Shin, Hyun Jin , Choi, Kyomin , Mauricio, Elizabeth A. , Cooper, Leslie T. , Gonsalves, Wilson I. , Witzig, Thomas E. , Lin, Yi , Rajkumar, S. Vincent , Gertz, Morie A. , Chao, Chi‐Chao , Lee, Ming‐Jen , Hsieh, Sung‐Tsang , Tsai, Li‐Kai , Yeh, Shin‐Joe , Yang, Chih‐Chao , Lee, Ga-Yeon , Cho, Eun Bin , Min, Ju‐Hong , Lee, Hye Lim , Kishida, Dai , Imai, Akira, Lin, Kon‐Ping, Wixner, Jonas, Suhr, Ole B. , Anan, Intissar , Nordh, Erik, Domellöf, Fátima Pedrosa , Chamova, Teodora , Schmidt, Hartmut , Tepasse, Phil‐Robin , Gillmore, Julian D. , Lachmann, Helen J. , Goh, Khean Jin , Geisler, Stephanie, Taylor, Mark, Suan, Dan

Mayo Clinic

JAMA Neurology | January 13, 2025 | Volume: 82 | Issue: 3 | Pages: 228

10.1001/jamaneurol.2024.4631 | PMID 39804640 Get It

Importance There is a lack of long-term efficacy and safety data on hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) and on RNA interference (RNAi) therapeutics in general. This study presents the longest-term data to date on patisiran for hATTR-PN. Objective To present the long-term efficacy and safety of patisiran in adults with hATTR-PN. Design, Setting, and Participants This global open-label extension (OLE) of the APOLLO randomized clinical trial and phase 2 OLE study enrolled patients from 43 hospitals or clinical centers across 19 countries between July 2015 and August 2017, with follow-up until November 2022. Of 212 eligible patients with hATTR who completed the phase 3 APOLLO or phase 2 OLE parent studies, 211 enrolled in and 138 completed the global OLE. Intervention Patisiran, 0.3 mg/kg, intravenously once every 3 weeks for up to 5 years. Main Outcomes and Measures Outcomes evaluated at year 5 of the global OLE included disability (polyneuropathy disability [PND] score); polyneuropathy severity (Neuropathy Impairment Score [NIS]), nutritional status (modified body mass index [mBMI]), quality of life (Norfolk Quality of Life–Diabetic Neuropathy [Norfolk QOL-DN]), and Rasch-Built Overall Disability Scale (R-ODS), with no statistical hierarchy. Safety, survival probability, and mortality were also assessed. Results At the global OLE baseline, the mean (SD) age was 61.3 (12.3) years, and 156 patients (73.9%) were male. In 138 patients completing the study, PND scores remained stable or improved in 89 patients (65.0%), NISs showed a mean (SD) change of 10.9 (14.7), and mean (SD) mBMI (calculated as weight in kilograms divided by height in meters squared times serum albumin in grams per liter) increased by 46.4 (120.7) over 5 years from baseline. Norfolk QOL-DN and R-ODS scores showed mean (SD) changes of 4.1 (16.7) and –3.7 (6.2), respectively. Adverse events (AEs) leading to study withdrawal occurred in 47 patients (22.3%). Infusion-related reactions were the most common treatment-related AE (n = 34 [16.1%]). Overall, 41 patients (19.4%) died during the study. Patisiran treatment in the parent study and low familial amyloid polyneuropathy score at parent study baseline were associated with significantly improved survival. Conclusions and Relevance In the longest study of an RNAi therapeutic for any disease, patisiran treatment resulted in modest changes for patients with hATTR-PN with an acceptable safety profile. These results highlight the importance of initiating early treatment for hATTR and the potential of RNAi therapeutics in medicine. Trial Registration ClinicalTrials.gov Identifier: NCT02510261
A 63 year-Old Male With a Painful Subacute Demyelinating Neuropathy
Blazek, Audrey M. , Griffin, Kim, Skolka, Michael, Toledano, Michel , Blazek Ramsay, Audrey , Pinto, Marcus Vinícius

Mayo Clinic

The Neurohospitalist | January 11, 2025 | Volume: 15 | Issue: 3 | Pages: 291-295

10.1177/19418744251314540 | PMID 39803330 Get It

Subacute, painful weakness is a common problem encountered by neurologists and can be associated with systemic symptoms. The patient presented with 6 weeks of progressive neuropathic pain followed by sensory changes and distal-predominant weakness. This case reviews the broad differential for such a presentation and a comprehensive, stepwise approach to diagnosis. Particular attention is paid to the potentially treatable polyradiculoneuropathies, including more recently recognized immune-mediated etiologies. Through this stepwise approach, we review how a definitive diagnosis was made.
Respiratory volume changes and CSF circulation during human NREM sleep
Lee, Jeyeon , Kandimalla, Mahathi, Ghatamaneni, Sujala, Dewan, Sannidhi, Gunter, Jeffrey L. , Graff‐Radford, Jonathan , Yook, Soonhyun , Kim, Hosung , Park, John G. , Lowe, Val J. , Min, Hoon‐Ki , Min, Hoon-Ki Paul , Lim, Seokbeen , Thakkar, Jay, Cogswell, Petrice M. , Botha, Hugo , McCarter, Stuart J. , Louis, Erik K. St. , Mantilla, Carlos B. , Huston, John

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S7 | Pages: No page available

10.1002/alz.093200 Get It

AbstractBackgroundSleep’s crucial role in maintaining brain health is increasingly recognized, particularly due to the rising prevalence of neurodegenerative diseases. It not only supports cognitive function but also aids in clearing brain metabolic waste through cerebrospinal fluid (CSF) dynamics. During sleep, especially in the non‐rapid eye movement (NREM) phase, CSF flow increases, essential for removing neurotoxic substances like amyloid‐beta proteins. This study explores the link between sleep respiratory patterns and CSF flow promotion.MethodElectroencephalography (EEG), and functional magnetic resonance imaging (fMRI) were simultaneously acquired during sleep from Gu, et al. (n = 29) (Gu et al. 2022). Respiration, measured via a respiratory belt, calculated respiratory volume (RV) as the standard deviation within a 5 second sliding window. EEG data processed delta band power (1‐4Hz) averaged across channels. Parcellated fMRI data using the brain template followed by the calculation of the averaged gray matter (GM) blood‐oxygen‐level‐dependent (BOLD) signal using the GM mask. CSF inflow was manually extracted from the fMRI’s bottom slice at the foramen magnum level. Subsequently, all signals were temporally aligned to the peak of the CSF inflow signal.ResultAt the time of CSF inflow (time = 0 sec. in the Figure 1A‐D), we observed an earlier increase in RV and EEG delta power, followed by changes in the GM BOLD signal (Figure 1). EEG and RV changes preceded the BOLD signal changes, which, in turn, preceded changes in CSF flow. Sensitivity to detect RV involvement during MRI varied with the placement of the respiratory belt, being least sensitive on the chest and more on the abdomen.ConclusionThese findings raise an interesting question on the role respiratory patterns during sleep, particularly in the NREM phase. Speculatively, RV change may influence CSF circulation during NREM sleep (Figure 1E). This enhancement in CSF flow is crucial for the clearance of metabolic waste from the brain, potentially reducing the risk of neurodegenerative diseases. Our findings indicate that respiratory volume may serve as a significant marker for CSF circulation during sleep.